FDA genehmigt Phase-II-Studie zu Natrunix bei Patienten mit rheumatoider Arthritis

May 22, 2023

https://www.globenewswire.com/news-release/2023/05/23/2673892/35550/de/FDA-genehmigt-Phase-II-Studie-zu-Natrunix-bei-Patienten-mit-rheumatoider-Arthritis.html

AUSTIN, Texas, May 23, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ:XBIT) vermeldet heute, dass das Unternehmen von der Abteilung für Rheumatologie der U.S. Food and Drug Administration (FDA) die Genehmigung für die Einleitung einer klinischen Phase-II-Studie zur Untersuchung von Natrunix™ bei rheumatoider Arthritis erhalten hat.

Read more at globenewswire.com

Related news for (XBIT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.